The objective of the proposed work is to develop an inhibitor of anthrax toxin that is effective in vivo and that is suitable for clinical use. Anthrax toxin is a combination of three proteins that are secreted separately by Bacillus anthracis and form toxic complexes that are internalized by mammalian cells. Protective antigen (PA) binds cellular receptors and is cleaved by furin-like proteases, which leads to the heptamerization of the cell-associated PA63 fragment. Heptamerization allows binding of the enzymatic toxin components, edema factor and lethal factor, and triggers endocytosis of these complexes and intoxication of the cells. Since anthrax toxin is an essential virulence factor and is responsible for the major symptoms and death from anthrax, the toxin is a prime target for therapeutic intervention. In particular, PA is an ideal target because it is the common component of the two toxins that comprise anthrax toxin, edema toxin and lethal toxin, which both induce tissue damage and cause death. We have attached multiple copies of a PA6s heptamer-binding inhibitory peptide to both poly-L-glutamic acid (PLGA) and liposomal scaffolds to generate polyvalent molecules that are several orders of magnitude more potent that the monomeric peptide in vitro and that neutralize anthrax toxin in vivo. The advantages of the polyvalent inhibitors described in this proposal are: 1) they block both toxins;2) they are synthesized from non-toxic scaffolds that are in routine clinical use (liposomes) or have been shown to be safe in clinical trials (PLGA);3) the synthetic processes are facile and scaleable;4) polyvalency provides a significant enhancement of potency;and 5) the PLGA-based inhibitors do not require a cold chain.
The first aim of this proposal is to optimize the in vivo efficacy of polyvalent anthrax toxin inhibitors. We will synthesize a limited number of PLGA-based and liposome-based inhibitors that exhibit high potencies in vitro and that differ in size (molecular weight of PLGA;diameter of liposomes), lipid composition (homogeneous and phase-separated liposomes) and/or peptide density to identify inhibitors that have optimal activities in toxin-challenge and spore-challenge animal models.
The second aim of this proposal is to perform preformulation studies to optimize inhibitor solubility and stability. Inhibitor solubility will be assessed in buffers made within a clinically suitable range of pH values, and in the presence of co- solvents and surfactants. Accelerated, intermediate and long term stability tests will be used to identify formulations most suitable for stockpiling of the inhibitor.
The third aim of this proposal is to determine the pharmacokinetics, tissue distribution, mass balance and toxicity of inhibitors. These data will assess the suitability of an inhibitor for clinical use and will be used to support an Investigational New Drug application. Relevance: The goal of this research is to develop a drug that blocks anthrax toxin. An anti-toxin therapeutic will be an important addition to the antibiotic therapy used to treat patients with anthrax.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Research Project--Cooperative Agreements (U01)
Project #
Application #
Study Section
Special Emphasis Panel (ZAI1-TP-M (J2))
Program Officer
Breen, Joseph J
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Toronto
Zip Code
M5 1-S8
Patke, Sanket; Boggara, Mohan; Maheshwari, Ronak et al. (2014) Design of monodisperse and well-defined polypeptide-based polyvalent inhibitors of anthrax toxin. Angew Chem Int Ed Engl 53:8037-40
Joshi, Amit; Kate, Sandesh; Poon, Vincent et al. (2011) Structure-based design of a heptavalent anthrax toxin inhibitor. Biomacromolecules 12:791-6
Kane, Ravi S (2010) Thermodynamics of multivalent interactions: influence of the linker. Langmuir 26:8636-40
Sriram, Shashikanth M; Banerjee, Rajkumar; Kane, Ravi S et al. (2009) Multivalency-assisted control of intracellular signaling pathways: application for ubiquitin- dependent N-end rule pathway. Chem Biol 16:121-31
Gujraty, Kunal V; Yanjarappa, Mallinamadugu J; Saraph, Arundhati et al. (2008) Synthesis of Homopolymers and Copolymers Containing an Active Ester of Acrylic Acid by RAFT: Scaffolds for Controlling Polyvalent Ligand Display. J Polym Sci A Polym Chem 46:7246-7257
Rai, Prakash; Vance, David; Poon, Vincent et al. (2008) Stable and potent polyvalent anthrax toxin inhibitors: raft-inspired domain formation in liposomes that contain PEGylated lipids. Chemistry 14:7748-51
Joshi, Amit; Vance, David; Rai, Prakash et al. (2008) The design of polyvalent therapeutics. Chemistry 14:7738-47
Li, Xuerong; Chen, Huiqing; Khan, Anwar A et al. (2008) Receptor-based identification of an inhibitory peptide against blood stage malaria. Biochem Biophys Res Commun 376:489-93
Joshi, Amit; Punyani, Supriya; Bale, Shyam Sundhar et al. (2008) Nanotube-assisted protein deactivation. Nat Nanotechnol 3:41-5
Rai, Prakash R; Saraph, Arundhati; Ashton, Randolph et al. (2007) Raftlike polyvalent inhibitors of the anthrax toxin: modulating inhibitory potency by formation of lipid microdomains. Angew Chem Int Ed Engl 46:2207-9

Showing the most recent 10 out of 14 publications